Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
14.86
-0.14 (-0.93%)
At close: Nov 6, 2026, 4:00 PM EST
14.82
-0.04 (-0.27%)
After-hours: Nov 6, 2026, 7:46 PM EST
Lyell Immunopharma Revenue
Lyell Immunopharma had revenue of $3.00K in the quarter ending September 30, 2026, a decrease of -80.00%. This brings the company's total for the last twelve months to $15.00K, down -63.41% year-over-year. In the year 2025, Lyell Immunopharma had annual revenue of $36.00K, down -40.98%. That makes Lyell Immunopharma the 47,181st largest company in the world by revenue and 7,138th in the United States.
Revenue (ttm)
$15.00K
Revenue Growth
-63.41%
P/S Ratio
24,356.10
Revenue / Employee
$93
Employees
161
Market Cap
365.34M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 36.00K | -25.00K | -40.98% |
| Dec 31, 2024 | 61.00K | -69.00K | -53.08% |
| Dec 31, 2023 | 130.00K | -84.55M | -99.85% |
| Dec 31, 2022 | 84.68M | 74.03M | 695.15% |
| Dec 31, 2021 | 10.65M | 2.89M | 37.31% |
| Dec 31, 2020 | 7.76M | 7.10M | 1,080.52% |
| Dec 31, 2019 | 657.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| C4 Therapeutics | 32.28M |
| Prelude Therapeutics | 22.42M |
| Opus Genetics | 9.86M |
| Allogene Therapeutics | 4.64M |
| ProKidney | 818.00K |
LYEL News
- 3 days ago - Lyell Immunopharma Transcript: Goldman Sachs’ RxChange Series: Framing Lyell’s next-generation lymphoma CAR-T data in 4Q - Transcripts
- 3 days ago - Lyell Immunopharma price target lowered to $35 from $36 at Stifel - TheFly
- 4 days ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026 - GlobeNewsWire
- 4 days ago - Why Is Lyell Immunopharma Stock (LYEL) Up over 43% Today? - TipRanks
- 4 days ago - Lyell Immunopharma to sell 7.43M shares at $10.77 in private placement - TheFly
- 4 days ago - Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission - GlobeNewsWire
- 4 days ago - Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma - GlobeNewsWire
- 4 days ago - Lyell Immunopharma Quarterly report: Q3 2026 - Filings